Kyverna Therapeutics, Inc.
$7.92 +$0.51 (+6.88%) 1D Pre-marketKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 27
A material event was filed (Form 8-K).
8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
RECEIPT: SEC FORM 8-K, TIMESTAMPED -
Jul 20
From its Apr 20 high, the share price fell 36%.
Peak close $11.25 on Apr 20; trough close $7.24 on Jul 20. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -36% -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Apr 21
The stock moved -13.7% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Apr 21 -
Mar 31
The stock moved +13.9% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Mar 31
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Kyverna Therapeutics, Inc.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.